Citations

Clear

1526 citation(s) found for "Sun, D".

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan

Mayo Clinic

Allergy, Asthma & Immunology Research | November 28, 2025 | Volume: 17 | Issue: 6 | Pages: 692

10.4168/aair.2025.17.6.692 | PMID 41330702 Get It

CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
Li, Hao , Luo, Jindan , Liang, Huaiyuan , Yanfeng, Bai , Liu, Jiandong , Wei, Ting , Wang, Liguo , Guo, Hongshan , Xia, Dan , Huang, Haojie , Sun, Rui , Bai, Yanfeng , Wang, Liguo , Huang, Rui , Wei, Ting , Liu, Jiandong , Sun, Rui

Mayo Clinic

Cancer Research | November 25, 2025 | Volume: 86 | Issue: 5 | Pages: 1180-1193

10.1158/0008-5472.can-25-1761 | PMID 41289556 Get It

Abstract CDK12 is frequently deleted and/or mutated in human cancers, and CDK12 inactivation is associated with aggressive phenotypes, including the tendency to metastasis. In this study, we showed that CDK12 deficiency induced intronic polyadenylation (IPA) usage in BRD4 to upregulate expression of the bromodomain-containing protein 4 (BRD4) short isoform (BRD4S). BRD4S demonstrated an enhanced capacity to form phase separation despite lacking the intrinsically disordered region located in the C-terminal of full-length BRD4. Oligomerization of BRD4S mediated phase separation through a base-interacting structural domain. CUT&Tag and RNA sequencing analyses revealed that BRD4S preferentially bound to the promoters of TGFβ signaling genes, including TGFB2 and LTBP1, driving their expression. Consistently, BRD4S drove cancer cell dissemination in vitro and metastasis in vivo, which could be blocked by BET or TGFβ signaling pathway inhibitors. Overall, this study identifies IPA usage at the BRD4 gene locus induced by CDK12 deficiency as a mechanism responsible for BRD4S genesis, which represents an important mechanism driving cancer metastasis and a potential target for therapeutic intervention in CDK12-deficient cancers. Significance: The CDK12–BRD4S–TGFβ signaling axis represents a key regulatory module that promotes metastatic progression and can be targeted by BET or TGFβ pathway inhibitors for treating CDK12-deficient cancers.
The nutrient-sensing Rag-GTPase complex in B cells controls humoral immunity via TFEB/TFE3-dependent mitochondrial fitness 2091
Wu, Yue , Li, Yanfeng , Sun, Jie , Zhu, Xingxing , Zhou, Xian , Shapiro, Virginia Smith , Sun, Jie , Boothby, Mark Robin , Zeng, Hu

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.055 Get It

Abstract Description During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3). However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 pathway as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells. Funding Sources National Institute of Allergy and Infectious Diseases (NIAID) - AI162678 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - AR077518 Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)
Robust Principal Component Analysis with Truncated Weighted Nuclear Norm and Adaptive Histogram Equalization: A Novel Method for Low-Quality Retinal Image Enhancement
Likassa, Habte Tadesse , Zhu, Wenhui , Dumitrascu, Oana M. , Sun, Dayu , Chen, Ding‐Geng , Chen, Kewei , Wang, Yalin

Mayo Clinic

Statistics and Data Science in Imaging | November 20, 2025 | Volume: 2 | Issue: 1 | Pages: No page available

10.1080/29979676.2025.2538438 Get It

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer
Nabid, Abdenour , Zapatero, Almudena, Bolla, M. , Joseph, David , Guerrero, A., Gonzalez, A. Alvarez, Segundo, Carmen González‐San , Rodríguez, María Ángeles Cabeza, Olivé, Agustí Pedro, Steigler, Allison , Souhami, Luís, Carrier, Nathalie , Armstrong, John G., Gillham, Charles, Pisansky, Thomas M. , Schipper, Matthew J. , Sandler, Howard M., Lawton, C.A., Roy, Soumyajit , Malone, Shawn , Hall, William A. , Shoag, Jonathan E. , Vince, Randy , García, Jorge A. , Mendiratta, Prateek, Valle, Luca , Dess, Robert T. , Jia, Angela Y. , Steinberg, Michael L. , Romero, Tahmineh , Kishan, Amar U. , Dess, Robert T , Zaorsky, Nicholas G. , Sun, Yilun , Zapatero, A. , Maingon, Philippe , Gonzalez San-Segundo, Carmen , Sole, Josep Maria, Efstathiou, Jason A. , Reijke, Theo M. de , Attard, Gerhardt , Morgan, Scott C. , Nguyen, Paul L. , Calaway, Adam , Barata, Pedro C. , Brown, Jason R. , Rettig, Matthew B. , Jackson, Will , Martin, Ting , Spratt, Daniel E.

Mayo Clinic

JAMA Oncology | November 20, 2025 | Volume: 12 | Issue: 1 | Pages: 58

10.1001/jamaoncol.2025.4800 | PMID 41264309 Get It

Importance The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. Objective To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. Data Sources This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. Study Selection For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. Data Extraction and Synthesis Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. Main Outcomes and Measures The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer–specific mortality, and other-cause mortality. Results The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer–specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. Conclusions and Relevance The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates.
Multidimensional Single-Cell Transcriptomic Profiling of Uterine Leiomyosarcomas Reveals Distinct Tumor States with Inferred Therapeutic Vulnerabilities
Korah, Maria, Agolia, James Paul , Reddy, Biren , Flojo, Renceh A. B., Wang, Lilin , Bethi, Rishik, Bobst, Wesley, Liang, Brooke, Yip, Kaylin A., Tabora, Angela D, Hsu, Chia-Hsin, Reveron‐Thornton, Rosyli F. , Guo, Chuner, Delitto, Andrea E., Xie, Peter Y., Tomasso, Antonio, Daniel, Sara K. , Litkouhi, Babak , Moding, Everett J. , Poultsides, George A. , Norton, Jeffrey A. , Charville, Gregory W. , Ganjoo, Kristen N. , Lee, Byrne , Longaker, Michael T., Gonçalves, Amanda Costa , Bethi, Rishik, Liang, Brooke, Yip, Kaylin A., Hsu, Chia-Hsin, Guo, Chuner, Gruener, Robert F. , Xie, Peter Y., Tomasso, Antonio, Sun, Beatrice J. , Dorigo, Oliver , Bui, Nam Q. , Pan, Minggui , Kalbasi, Anusha K. , Kirane, Amanda , Newman, Aaron M. , Foster, Deshka S. , Huang, R. Stephanie , Delitto, Daniel

Mayo Clinic

No container title available | November 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.11.17.688894 Get It

Abstract Uterine leiomyosarcoma (ULMS) is an orphan disease that frequently recurs and metastasizes, with patients undergoing multiple lines of chemotherapy due to lack of effective therapeutic targets. To address this gap, we used single-cell RNA sequencing and spatial transcriptomic analysis to comprehensively profile ULMS. We uncovered multiple states of tumor cells, including tumor cells with mesenchyme-like features, ischemic tumor cells defined by a MYC program, inflammatory tumor cells with active interferon signaling, and stem cell-like hormone receptor-positive cells. The inferred spatial correlates of these tumor cell states demonstrated unique localization patterns. By correlating these signatures to bulk RNA sequencing data, we demonstrate the relevance of these findings to clinical outcomes. Finally, using the single-cell integration and drug response prediction algorithm (scIDUC), we propose drug predictions that may target specific tumor states. Our findings suggest new avenues for further exploration of individualized and multifaceted therapeutic strategies to treat ULMS.
EXTH-145. Chimeric Antigen Receptor-Engineered Extracellular Vesicles from Human Stem Cell-Derived Neutrophils for Glioblastoma Therapy
Michaelides, Loizos , Esmonde, Colin , Xiaoping, Bao, Sun, Li , Chang, Yun , Zeng, Changchun , ReFaey, Karim , Li, Yan

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v373-v373

10.1093/neuonc/noaf201.1476 Get It

Abstract Glioblastoma (GBM) is the most common malignant tumor of the CNS, accounting for 80% of brain tumors. Recent advances in gene editing and immunology have led to the development of chimeric antigen receptors (CARs), including CARs incorporating chlorotoxin (CLTX) receptor domains for GBM targeting. While CAR-engineered neutrophils have shown promise, their systemic administration can induce severe off-target effects. Extracellular vesicles (EVs), secreted by these cells, retain properties of their parent cells—including CAR expression and tumor-lytic activity—yet their potential has not been explored in CAR Neutrophils. To address this, CAR-CLTX DNA was inserted into the AAV1 safe harbor locus of induced pluripotent stem cells, which were subsequently differentiated into neutrophils. Conditioned media were collected during differentiation and processed using extraPEG-based EV isolation. EVs were quantified via nanoparticle tracking analysis, electron microscopy, and western blotting. Proteomic and microRNA (miRNA) profiling of EV cargo was conducted at days 12 and 21 of differentiation. Cytotoxic effects of EVs were assessed in U87MG and LN229 glioblastoma cells in 2D culture, 3D organoids, and in vivo models. EVs were secreted in high quantities within the 100–200 nm size range, expressed canonical exosomal markers, and exhibited characteristic morphology. Proteomic analysis identified neutrophil-associated proteins involved in migration, chemotaxis, and degranulation. miRNA sequencing revealed high levels of tumor-suppressive miRNAs (e.g., miR-182) implicated in apoptotic signaling, T cell receptor pathways, cytokine-cytokine receptor interactions, Jak-STAT, Hedgehog, and NK cell-mediated cytotoxicity. EV uptake by glioma cells was demonstrated in vitro. Cytotoxic effects of CAR Neutrophil EVs were observed across glioblastoma cell lines, organoids, and in vivo. These findings demonstrate that CAR Neutrophil-derived EVs carry anti-tumor protein and miRNA cargo, are efficiently taken up by GBM cells, and mediate glioma cell cytotoxicity. This supports the feasibility of correlating EV cargo composition with function in GBM treatment.
Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence
Jain, Sneha S. , Sun, Tony , Pierson, Emma , Oliver, F. , Malta, Paloma P , Castillo, Michelle , Wan, Ningxin, Alishetti, Shudhanshu , Finer, Joshua , Brown, Kathleen LaRow , Ramlall, Vijendra , Elhadad, Noémie , Rodríguez, Fátima , Homma, Shunichi, Poterucha, Timothy J. , Poterucha, Timothy Joseph , Hartman, Heidi S. , Tatonetti, Nicholas P. , Witteles, Ronald , Goyal, Parag , Einstein, Andrew Jeffrey , Maurer, Matthew J. , Elias, Pierre

Mayo Clinic

JAMA Cardiology | November 10, 2025 | Volume: 11 | Issue: 2 | Pages: 117

10.1001/jamacardio.2025.4591 | PMID 41213043 Get It

Importance Transthyretin amyloid cardiomyopathy (ATTR-CM) is underdiagnosed despite expanding treatment options. Objective To develop and evaluate an artificial intelligence (AI)–augmented clinical program for ATTR-CM detection. Design, Setting, and Participants This nonrandomized clinical trial involved constructing an AI model, ATTRACTnet, using electrocardiogram waveforms, echocardiographic measurements, demographics, and diagnosis codes for orthopedic manifestations of amyloidosis. A single-system, multisite, single-arm, open-label trial was conducted to evaluate its real-world performance. The model was trained and validated at a large academic referral site for ATTR-CM with external validation at an academic site. The trial was conducted as a single-system, multisite trial. Patients with left ventricular (LV) wall thickness 12 mm or more and an ATTRACTnet score 0.5 or higher were eligible. Exclusions included prior ATTR-CM testing, hypertrophic cardiomyopathy, expected life span less than 1 year, nursing home residence, advanced dementia, or LV wall thickness less than 14 mm explained by uncontrolled hypertension or moderate/severe aortic stenosis. Intervention Eligible patients were notified and offered nuclear scintigraphy testing, monoclonal protein testing, and follow-up care on agreement from the treating physician. Main Outcomes and Measure The primary outcome was a diagnosis of ATTR-CM by consensus criteria. ATTR-CM testing positivity was compared with historical and contemporary controls. Results ATTRACTnet was developed in an internal test set of 799 patients (mean [SD] age, 75.1 [11.1] years; 516 [64.7%] male and 283 [35.3%] female) using 5-fold cross-validation with an additional external test set of 422 patients. It had good discrimination for ATTR-CM detection with an area under the receiver operator characteristic curve of 0.85 (5-fold cross-validation, 0.77-0.85) in the internal set and 0.82 (95% CI, .81-0.83) in the external test set with similar performance in Hispanic, non-Hispanic Black, and non-Hispanic White patients. A total of 1471 patients were identified with positive AI model scores 0.5 or more during the study period, with 256 eligible patients who met study criteria. Of these patients, 50 underwent amyloidosis testing after physician and patient approval; 24 (48%) were diagnosed with ATTR-CM, and 21 (88%) initiated treatment within 3 months. The positivity rate was more than 2.8 times higher than historical controls (15.3%; 95% CI, 13.1%-17.9%; P < .001), with an 18% relative increase in new diagnoses vs the prior year. Conclusions and Relevance AI-augmented screening may improve ATTR-CM detection and identify patients who are missed by usual care. Prospective randomized trials are needed to determine if outcomes are improved. Trial Registration ClinicalTrials.gov Identifier: NCT06469372
SPIROMICS HF: Rationale, Design, and Reproducibility of Measures
Barr, R. Graham , Lima, João A.C. , Prince, Martin R. , Abraham, Theodore P. , Agarwal, Prachi , Arora, Garima , Balasubramanian, Aparna , Barjaktarević, Igor , Bello, Natalie A. , Carr, James C. , Cooper, Christopher B. , Finn, J. Paul , Freed, Benjamin H. , Hansel, Nadia N. , Hsu, Jeffrey J. , Kitzman, Dalane W. , LaBounty, Troy , Lee, Yoo Jin , Liu, Jing , Lloyd, Steven G. , Markl, Michael , Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Schroeder, Joyce , Shepshelovich, Daniel , Sun, Yifei , Wells, J. Michael , Wieben, Oliver , Woodruff, Prescott G. , Ambale-Venkatesh, Bharath , Agarwal, Prachi P , Arora, Garima , Balasubramanian, Aparna , Barjaktarevic, Igor , Bello, Natalie A , Bluemke, David A , Budoff, Matthew , Carr, James C , Chaudhuri, Dipayan , Cooper, Christopher B , Couper, David , Finn, J Paul , Freed, Benjamin H , Han, MeiLan King , Hansel, Nadia N , Hsu, Jeffrey J , Kitzman, Dalane W , Krishnan, Jerry A , LaBounty, Troy M , Lee, Yoo Jin , Liu, Jing , Lloyd, Steven G , Mukherjee, Monica , Beussink-Nelson, Lauren , Ohar, Jill , Paine, Robert , Schroeder, Joyce D , Shen, Wei , Sun, Yifei , Vogel-Claussen, Jens , Watson, Karol E. , Wells, J Michael , Wieben, Oliver , Woodruff, Prescott G , Shah, Sanjiv J , Markl, Michael , Barr, R. Graham , Bluemke, David A. , Budoff, Matthew J. , Couper, David , Mukherjee, Monica , Vogel‐Claussen, Jens

Mayo Clinic

Circulation: Heart Failure | November 5, 2025 | Volume: 18 | Issue: 12 | Pages: No page available

10.1161/circheartfailure.125.012833 | PMID 41190426 Get It

BACKGROUND: Although chronic obstructive pulmonary disease (COPD) and heart failure with preserved ejection fraction often coexist with overlapping clinical features, they are usually studied separately. The SPIROMICS HF (Subpopulations and Intermediate Outcome Measures in COPD and Heart Failure Study) is testing hypotheses that new computed tomography emphysema subtypes are associated with specific cardiovascular phenotypes (eg, cor pulmonale , cor pulmonale parvus ), common airway branch variants are associated with right heart dysfunction, and symptomatic tobacco-exposed persons with preserved spirometry have signs of increased left ventricular afterload. METHODS: SPIROMICS is a multicenter observational study of COPD with extensive pulmonary phenotyping of participants with ≥20 pack-years smoking and nonsmoking controls. COPD and COPD severity were defined by standard spirometric criteria and symptomatic tobacco-exposed persons with preserved spirometry by ≥20 pack-years, normal spirometry, and COPD Assessment Test score >10. SPIROMICS HF selected all participants in SPIROMICS visit 5 at major sites. Its comprehensive speckle-tracking echocardiography, which included physiological perturbations of leg raise and low-intensity exercise, was harmonized prospectively with the Multi-Ethnic Study of Atherosclerosis Early Heart Failure and HeartSHARE (Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets) studies. The cardiopulmonary magnetic resonance imaging protocol with gadolinium administration included myocardial fibrosis sequences, pulmonary angiography, time-resolved 3-dimensional cine magnetic resonance imaging (4-dimensional flow) of venous return, and metronome-paced tachypnea to induce dynamic hyperinflation. Coronary artery calcium was assessed on computed tomography scans. The Kansas City Cardiomyopathy Questionnaire was administered. RESULTS: Of the final sample of 753 participants, 57% had COPD (15% mild, 27% moderate, and 15% severe), 18% had symptomatic tobacco-exposed persons with preserved spirometry, 16% were smoking controls, and 8% were nonsmoking controls. Reproducibility of the main measures from speckle-tracking echocardiography (intraclass correlation coefficient, 0.83–0.99), exercise echocardiography (intraclass correlation coefficient, 0.71–0.99) and magnetic resonance imaging (intraclass correlation coefficient, 0.57–0.99) were good-to-excellent, including in severe COPD. CONCLUSIONS: SPIROMICS HF aims to characterize and understand cardiopulmonary interactions in COPD and COPD-related phenotypes to inform targeted treatments for combined cardiopulmonary failure.
Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
Li, Changying , Zhao, X.-M. , Li, Xinyan , Wang, Chunyan , Huo, Zhenyu , Xu, Xin , Kang, Wenjuan , Nowsheen, Somaira , Aziz, Khaled , Sun, Guang-Yi , Deng, Min , Zhao, Xuran , Sun, Guangyi , Liu, Zhihua , Lou, Zhenkun , Deng, Min , Li, Changying , Wang, Chunyan , Kang, Wenjuan , Lou, Zhenkun

Mayo Clinic

Cancer Research | November 3, 2025 | Volume: 86 | Issue: 3 | Pages: 730-745

10.1158/0008-5472.can-25-1435 | PMID 41183146 Get It

Abstract Pancreatic adenocarcinoma remains one of the most lethal malignancies, primarily due to its robust resistance to genotoxic therapies, such as chemotherapy and radiotherapy. Understanding the mechanisms underlying this resistance is essential to improve clinical outcomes. In this study, we identified trimethylguanosine synthase 1 (TGS1), previously known for its role in RNA modification, as a critical mediator of homologous recombination (HR) repair that specifically contributes to resistance in pancreatic adenocarcinoma. TGS1 was significantly overexpressed in pancreatic adenocarcinoma tissues, correlating strongly with advanced disease stages, therapy resistance, and poor patient prognosis. Following DNA damage, ATM kinase phosphorylated TGS1 at serine residues S389 and S531, which mediated its direct interaction with BRCA1 and subsequent recruitment of BRCA1 to DNA damage sites. The phosphorylation-dependent interaction enhanced HR repair efficiency, enabling cancer cells to survive genotoxic stress. Depletion or pharmacologic inhibition of TGS1 induced HR deficiency and markedly enhanced sensitivity to DNA-damaging agents, particularly PARP inhibitors, in pancreatic adenocarcinoma cell lines in vitro and in both cell line– and patient-derived xenograft models in vivo. Collectively, these findings uncover an ATM–TGS1–BRCA1 signaling axis that promotes DNA repair and resistance to genotoxic therapies in pancreatic cancer, positioning TGS1 as a promising predictive biomarker and therapeutic target to enhance treatment efficacy. Significance: The ATM–TGS1–BRCA1 signaling axis is a critical regulator of DNA repair that can be targeted to overcome genotoxic therapy resistance, providing a promising therapeutic strategy that could transform pancreatic cancer treatment.